Celina Wakisaka Maruta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celina Wakisaka Maruta has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Valeria Aoki
Department of Dermatology, University of São Paulo School of Medicine, São Paulo, Brazil
13 shared publications - Claudia Giuli Santi
Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
11 shared publications - Denise Miyamoto
Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
9 shared publications - Natasha Favoretto Dias de Oliveira
Private Practice in Dermatology , São Paulo
3 shared publications - Bernardo Gontijo
UFMG
2 shared publications - Cecília Mirelle Almeida Honorato
Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
2 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Penfigoide bolhoso: análise epidemiológica, clínica e terapêutica de 189 pacientes em centro terciário no Brasil
- 21 August 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (5)
Open AccessPenfigoide bolhoso: análise epidemiológica, clínica e terapêutica de 189 pacientes em centro terciário no Brasil
- Open Access
- 18 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501163
Bullous pemphigoid: epidemiological, clinical, and therapeutic analysis of 189 patients in a tertiary center in Brazil
- 18 July 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (5) , 501163
Open AccessBullous pemphigoid: epidemiological, clinical, and therapeutic analysis of 189 patients in a tertiary center in Brazil
- 22 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Evaluation of pruritus biomarkers expression in chronic spontaneous urticaria
Chronic urticaria (CU) is a skin disease characterized by recurrent episodes of urticaria and/or angioedema, persisting for more than six weeks. Chronic urticaria is classified as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Histamine, released by mast cells and basophils, is the central mediator in the development of signs and symptoms, especially pruritus. IL-31 activates pruritus via IL-31RA. Th2 cytokines also contributes to the inflammatory environment, releasing further IL-31. We aimed to investigate the quantification of mast cells, expression of pro-inflammatory cytokines in skin samples from individuals with CU and cell activation by the basophil activation test. Thirteen patients with CSU, 11 patients with CIndU and 10 healthy controls (HC) were enrolled in the study. We performed histologic quantification of the mast cells, metachromatic stained with toluidine blue, in CSU and CIndU lesional samples; IL-31, IL-31RA, IL-4 and IFN-γ expression by immunohistochemistry; and basophil activation test (BAT) by flow cytometry. The main findings were increased mast cell quantification in CSU; increased epidermal and dermal expression of IL-31 in CSU lesional samples and increased dermal expression in CIndU samples; augmented IL-31RA expression at epidermis and dermis of CSU group; augmented expression IL-4 at epidermis of CSU patients. We also found enhanced BAT positivity in CSU, reinforcing the autoimmune profile of our CSU patients. The analysis of the proinflammatory cytokines related to pruritus, showed increased expression of the evaluated components. These remarkable findings in CSU emphasize their relevance as potential disease biomarkers and targets for immunomodulatory interventions.
- 22 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-4
Evaluation of pruritus biomarkers expression in chronic spontaneous urticaria
Chronic urticaria (CU) is a skin disease characterized by recurrent episodes of urticaria and/or angioedema, persisting for more than six weeks. Chronic urticaria is classified as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Histamine, released by mast cells and basophils, is the central mediator in the development of signs and symptoms, especially pruritus. IL-31 activates pruritus via IL-31RA. Th2 cytokines also contributes to the inflammatory environment, releasing further IL-31. We aimed to investigate the quantification of mast cells, expression of pro-inflammatory cytokines in skin samples from individuals with CU and cell activation by the basophil activation test. Thirteen patients with CSU, 11 patients with CIndU and 10 healthy controls (HC) were enrolled in the study. We performed histologic quantification of the mast cells, metachromatic stained with toluidine blue, in CSU and CIndU lesional samples; IL-31, IL-31RA, IL-4 and IFN-γ expression by immunohistochemistry; and basophil activation test (BAT) by flow cytometry. The main findings were increased mast cell quantification in CSU; increased epidermal and dermal expression of IL-31 in CSU lesional samples and increased dermal expression in CIndU samples; augmented IL-31RA expression at epidermis and dermis of CSU group; augmented expression IL-4 at epidermis of CSU patients. We also found enhanced BAT positivity in CSU, reinforcing the autoimmune profile of our CSU patients. The analysis of the proinflammatory cytokines related to pruritus, showed increased expression of the evaluated components. These remarkable findings in CSU emphasize their relevance as potential disease biomarkers and targets for immunomodulatory interventions.
- Open Access
- 26 February 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRC0699
Azacitidine-induced bullous pemphigoid-like localized toxic reaction
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation (allo-SCT) and presented with a rare and previously unreported cutaneous side effect after the use of subcutaneous azacitidine. We propose that changing the route of azacitidine administration from subcutaneous to intravenous could potentially decrease the occurrence of bullous pemphigoid-like localized toxic reactions in some
- 26 February 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRC0699
Open AccessAzacitidine-induced bullous pemphigoid-like localized toxic reaction
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation (allo-SCT) and presented with a rare and previously unreported cutaneous side effect after the use of subcutaneous azacitidine. We propose that changing the route of azacitidine administration from subcutaneous to intravenous could potentially decrease the occurrence of bullous pemphigoid-like localized toxic reactions in some
- Open Access
- 1 September 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (5) , 581-590
Doenças bolhosas autoimunes na gestação: características clínicas, epidemiológicas e abordagem terapêutica
- 1 September 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (5) , 581-590
Open AccessDoenças bolhosas autoimunes na gestação: características clínicas, epidemiológicas e abordagem terapêutica
- Open Access
- 23 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 581-590
Autoimmune bullous diseases in pregnancy: clinical and epidemiological characteristics and therapeutic approach
- 23 July 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (5) , 581-590
Open AccessAutoimmune bullous diseases in pregnancy: clinical and epidemiological characteristics and therapeutic approach
- 5 July 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , 1569-1573
Recurrent erythema multiforme: A therapeutic proposal for a chronic disease
Recurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical–epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty‐five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow‐up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2–6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long‐term therapeutic protocol to enable disease remission.
- 5 July 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , 1569-1573
Recurrent erythema multiforme: A therapeutic proposal for a chronic disease
Recurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical–epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty‐five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow‐up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2–6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long‐term therapeutic protocol to enable disease remission.
- Open Access
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (1) , 76-81
Células dendríticas plasmocitoides na dermatologia
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (1) , 76-81
Open AccessCélulas dendríticas plasmocitoides na dermatologia
- Open Access
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (1) , 76-81
Plasmacytoid dendritic cells in dermatology
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (1) , 76-81
Open AccessPlasmacytoid dendritic cells in dermatology
- Open Access
- 1 November 2019
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 94 (6) , 724-728
Abordagem diagnóstica da espongiose eosinofílica
- 1 November 2019
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 94 (6) , 724-728
Open AccessAbordagem diagnóstica da espongiose eosinofílica